PIXITMEDIA
17.11.2022 17:41:35 CET | Business Wire | Press release
Leading software-defined storage and data management solution provider, pixitmedia, a Kalray company, and Lenovo, the Fortune Global 500 technology powerhouse, are now offering a cost-effective and ultra-scalable cloud-enabled hyper-converged solution to the Media and Entertainment industry. Hyper-converged, or HCI, unites pixitmedia’s award-winning software, pixstor™ with ngenea®, with Lenovo’s smart solutions into a single appliance, with guaranteed performance suitable for a multitude of Media and Entertainment workflows.
Historically, studios have depended on storage products supplied by major data appliance vendors. Most vendors are either yet to evolve cloud-based solutions or offer very limited cloud capabilities. This is restrictive and limits the flexibility of media creation companies as their businesses grow and content delivery models change. Having a hyper-converged infrastructure gives studios the freedom to choose where to grow their capabilities, whether it be on-premise or in the cloud. Those working remotely should have the same experience as those who choose to work on-premises and vice versa. For companies operating virtual workstations, this is a vital part of the workflow, and it is where dynamic data management can bring huge benefits. A hyper-converged approach allows creative media businesses to stay agile and keep infrastructure costs low by virtualising key elements of conventional “hardware-defined” systems.
“pixitmedia and Lenovo liberate Media and Entertainment businesses from being locked into restrictive data environments. Studios that are able to quickly adjust infrastructure, keep up with productivity and meet content demands, are able to stay competitive. A hyper-converged approach enables creative media businesses of any size to stay agile and keep infrastructure costs lower" explains Ben Leaver, EVP of Business Development, pixitmedia.
“The Media and Entertainment sector is a complex and exciting industry and Lenovo is committed to working with partners to create solutions which offer customers value. In collaboration with pixitmedia we’ve developed a solution which makes it easy for companies in this sector to deploy a hyper-converged environment.” says Ian Jeffs, UK and Ireland General Manager, Lenovo Infrastructure Solutions Group.
The collaboration between pixitmedia and Lenovo has resulted in a Hyperconverged solution that guarantees customers complete control of their data. All users can see and access the same data securely, enabling rock-solid collaboration between multiple creative sites. The solution enables businesses a simplistic transition to cloud and hybrid ways of working with no disruption to existing workflows and no compromise on security, whilst delivering guaranteed ultra-fast performance. For ultimate flexibility, the pixitmedia HCI solution works with any cloud provider over a multitude of production workflows, giving the customer the flexibility to scale up or down according to projects. pixitmedia, a global leader in cloud-workflow solutions for Media and Entertainment, has already deployed multiple hybrid solutions to over 20 global media production and distribution companies.
The solution works seamlessly across multiple operating systems and leverages cloud providers’ networks for ultra-high-speed data transfers, businesses can easily expand on-premises pipelines into the cloud with a software-defined solution such as pixstor™, while still enjoying the guaranteed sustained collaboration, performance, scalability and intelligent management tools of an on-premises deployment. Supported by ngenea®, an intelligent data transport mechanism, business experiences can be tightly integrated on-premises, and cloud infrastructure integrated under a single namespace.
By adopting integrated cloud solutions such as ngenea® and pixstor™, media creation businesses will have everything that they need, from on-premises to remote working and everything in between. pixitmedia also offers an upgrade path for the HCI solution to scale-out NAS as your business grows to give customers that added flexibility for the future.
Working together with Lenovo is about driving business forward and empowering customer workflows. Hyper-converged infrastructure offers scalability and agility, optimised performance and collaboration and the option to reduce costs. In simple terms, it gives media enterprises more choices, more collaborative efficiencies and more freedom than ever before.
For more information on pixitmedia and Lenovo HCI solutions please visit: pixitmedia.com/lenovo/
ABOUT LENOVO
Lenovo (HKSE: 992) (ADR: LNVGY) is a US$70 billion revenue global technology powerhouse, ranked #171 in the Fortune Global 500, employing 75,000 people around the world, and serving millions of customers every day in 180 markets. Focused on a bold vision to deliver smarter technology for all, Lenovo has built on its success as the world’s leading PC player by expanding into new growth areas of infrastructure, mobile, solutions and services. This transformation together with Lenovo’s world-changing innovation is building a more inclusive, trustworthy, and sustainable digital society for everyone, everywhere.
ABOUT PIXITMEDIA
pixitmedia is a Kalray company (Euronext Growth Paris: ALKAL), a leading provider of hardware and software technologies and solutions for high-performance, data-centric computing markets, from cloud to edge. pixitmedia and Kalray share a common vision and a complementary value proposition in both software and hardware to address today’s and tomorrow’s data-intensive world with solutions for a more intelligent, effective, energy-wise and user-friendly data-driven world.
pixitmedia’s award-winning purpose-built, software-defined storage and data solutions simplify the flow of data to connect an increasingly complex world. We devise optimized solutions that give customers both choice and freedom, our restless innovation constantly pushes boundaries and the unrivalled care and knowledge of our team ensure optimum performance and value. Customer success is at the heart of our business, we have technical specialists and a unique, dedicated lab facility to guarantee the effectiveness of our solutions. For more information, please visit https://pixitmedia.com or contact us: marketing@pixitmedia.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221117005654/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom